French President Francois Hollande, faced with a rebellion within his ruling Socialist Party, dissolved his cabinet and swore to start afresh. Hollande’s popularity rating is only 17 percent
The new Roamio OTA costs $50, plus $15 per month
The founder of a Hong Kong democracy movement has kicked off a furor by saying he would welcome police use of tear gas and water cannon to suppress a possible march by activists
In the biggest acquisition in Amazon's history, the online retailer pays $970 million for Twitch, which Googled courted for months
It’s a psychological threshold, but the 2K mark has no particular significance for buy-and-hold investors
A human cannot copyright the work of an animal—or, for that matter, the ocean
With its new site, Like2Buy, Nordstrom wants to make shopping easier for Instagram followers
Before students at Stanford's business school arrive on campus, most of them will spend a week together in Colombia on a trip that has become an unwritten tradition at the school
Small independent vintners who stored wine barrels in shared facilities were closer to the California earthquake's epicenter
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."